(Q35354493)

7 August 2017

1 reference

title

Safety aspects in the manufacturing of plasma-derived coagulation factor concentrates (English)

1 reference

7 August 2017

1

T. Burnouf

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1389114

21 September 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1389114

21 September 2022

publication date

1 June 1992

1 reference

7 August 2017

1 reference

7 August 2017

volume

20

1 reference

7 August 2017

issue

2

1 reference

7 August 2017

page(s)

91-100

1 reference

Acute hepatitis non-A, non-B following administration of factor VIII concentrates

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1045-1056%2805%2980056-9

7 January 2021

Non-A non-B hepatitis after transfusion of factor VIII in infrequently treated patients

1 reference

https://api.crossref.org/works/10.1016%2FS1045-1056%2805%2980056-9

7 January 2021

Transmission of serum parvovirus-like virus by clotting-factor concentrates

1 reference

https://api.crossref.org/works/10.1016%2FS1045-1056%2805%2980056-9

7 January 2021

The development of virus-free labile blood derivatives--a review

1 reference

https://api.crossref.org/works/10.1016%2FS1045-1056%2805%2980056-9

7 January 2021

Reduction in risk of hepatitis transmission by heat-treatment of a human Factor VIII concentrate.

1 reference

https://api.crossref.org/works/10.1016%2FS1045-1056%2805%2980056-9

7 January 2021

Transmission of non-A, non-B hepatitis by heat-treated factor VIII concentrate

1 reference

https://api.crossref.org/works/10.1016%2FS1045-1056%2805%2980056-9

7 January 2021

Non-A, non-B hepatitis and heat-treated factor VIII concentrates

1 reference

https://api.crossref.org/works/10.1016%2FS1045-1056%2805%2980056-9

7 January 2021

Transmission of human immunodeficiency virus type 1 by dry-heated clotting factor concentrates. Transfusion Safety Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1045-1056%2805%2980056-9

7 January 2021

Inactivation of viruses in labile blood derivatives. II. Physical methods

1 reference

https://api.crossref.org/works/10.1016%2FS1045-1056%2805%2980056-9

7 January 2021

Thermal inactivation by sequential dry-heat treatments at sterilizing temperatures (100 degrees C-boiling) of factor VIII and factor IX concentrates to produce sterile concentrates

1 reference

https://api.crossref.org/works/10.1016%2FS1045-1056%2805%2980056-9

7 January 2021

Virucidal treatment of clotting factor concentrates

1 reference

https://api.crossref.org/works/10.1016%2FS1045-1056%2805%2980056-9

7 January 2021

Absence of hepatitis after treatment with a pasteurized factor VIII concentrate in patients with hemophilia and no previous transfusions

1 reference

https://api.crossref.org/works/10.1016%2FS1045-1056%2805%2980056-9

7 January 2021

Low risk for hepatitis C in hemophiliacs given a high-purity, pasteurized factor VIII concentrate. International Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1045-1056%2805%2980056-9

7 January 2021

Acute hepatitis B infection after treatment with heat-inactivated factor VIII concentrate

1 reference

https://api.crossref.org/works/10.1016%2FS1045-1056%2805%2980056-9

7 January 2021

Inactivation of viruses in labile blood derivatives. I. Disruption of lipid-enveloped viruses by tri(n-butyl)phosphate detergent combinations

1 reference

https://api.crossref.org/works/10.1016%2FS1045-1056%2805%2980056-9

7 January 2021

Virus safety of solvent/detergent-treated antihaemophilic factor concentrate

1 reference

https://api.crossref.org/works/10.1016%2FS1045-1056%2805%2980056-9

7 January 2021

A highly purified factor VIII:c concentrate prepared from cryoprecipitate by ion-exchange chromatography

1 reference

https://api.crossref.org/works/10.1016%2FS1045-1056%2805%2980056-9

7 January 2021

Chromatographic preparation of a therapeutic highly purified von Willebrand factor concentrate from human cryoprecipitate

1 reference

https://api.crossref.org/works/10.1016%2FS1045-1056%2805%2980056-9

7 January 2021

Inactivation of human immunodeficiency virus by gamma radiation and its effect on plasma and coagulation factors

1 reference

https://api.crossref.org/works/10.1016%2FS1045-1056%2805%2980056-9

7 January 2021

Methods for the production of clinically effective intermediate- and high-purity factor-VIII concentrates

1 reference

https://api.crossref.org/works/10.1016%2FS1045-1056%2805%2980056-9

7 January 2021

Inactivation of HTLV-III/LAV during plasma fractionation

1 reference

https://api.crossref.org/works/10.1016%2FS1045-1056%2805%2980056-9

7 January 2021

Lack of seroconversion for LAV/HTLV-III in patients exclusively given unheated activated prothrombin complex prepared with ethanol step

1 reference

https://api.crossref.org/works/10.1016%2FS1045-1056%2805%2980056-9

7 January 2021

A novel method for removal of human immunodeficiency virus: filtration with porous polymeric membranes

1 reference

https://api.crossref.org/works/10.1016%2FS1045-1056%2805%2980056-9

7 January 2021

Properties of a highly purified human plasma factor IX:c therapeutic concentrate prepared by conventional chromatography

1 reference

https://api.crossref.org/works/10.1016%2FS1045-1056%2805%2980056-9

7 January 2021

Chromatographic removal of hepatitis B virus from a factor IX concentrate. Experimental studies in chimpanzees

1 reference

https://api.crossref.org/works/10.1016%2FS1045-1056%2805%2980056-9

7 January 2021

Removal of non-A, non-B hepatitis virus from a concentrate of the coagulation factors II, VII, IX and X by hydrophobic interaction chromatography

1 reference

https://api.crossref.org/works/10.1016%2FS1045-1056%2805%2980056-9

7 January 2021

Hepatitis C virus transmission by monoclonal antibody purified factor VIII concentrate

1 reference

https://api.crossref.org/works/10.1016%2FS1045-1056%2805%2980056-9

7 January 2021

Anaphylactic reactions following infusion of factor VIII in a patient with classic hemophilia

1 reference

https://api.crossref.org/works/10.1016%2FS1045-1056%2805%2980056-9

7 January 2021

Adverse reactions to factor VIII infusions

1 reference

https://api.crossref.org/works/10.1016%2FS1045-1056%2805%2980056-9

7 January 2021

Some characteristics of aggregates of IgG and plasma proteins in heat-treated factor VIII concentrates

1 reference

https://api.crossref.org/works/10.1016%2FS1045-1056%2805%2980056-9

7 January 2021

Inhibitors to monoclonal antibody purified factor VIII.

1 reference

https://api.crossref.org/works/10.1016%2FS1045-1056%2805%2980056-9

7 January 2021

No activation of the common pathway of the coagulation cascade after a highly purified factor IX concentrate

1 reference

https://api.crossref.org/works/10.1016%2FS1045-1056%2805%2980056-9

7 January 2021

Detection of HIV-1 RNA in factor VIII concentrate

1 reference

https://api.crossref.org/works/10.1016%2FS1045-1056%2805%2980056-9

7 January 2021

Detection, quantification and sequencing of HIV-1 from the plasma of seropositive individuals and from factor VIII concentrates

1 reference

https://api.crossref.org/works/10.1016%2FS1045-1056%2805%2980056-9

7 January 2021

10.1016/S1045-1056(05)80056-9

Identifiers

DOI

1 reference

7 August 2017

1 reference